New Science Ventures
New Science Ventures is a venture capital firm focused on investments in life sciences and information technology companies.
Business Model:
Revenue: $1.5M
Employees: 2-10
Rankings
Industries / Tags:
Detailed New Science Ventures Information
Geographic Data
Address: 610 5th Ave
City: New York
State: NY
Zip: 10020
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$14M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companies using science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Contact Phone:
+12126613498
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2018 | Svelte Medical Systems | Venture Round | 22M |
| 10/2007 | Ikonisys | Series E | 30M |
| 9/2018 | ISORG | Series B | 0 |
| 6/2010 | ProterixBio | Series D | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 11/2013 | BrightVolt | Series A | 0 |
| 1/2011 | Celleration | Series E | 0 |
| 3/2006 | Ikonisys | Series D | 0 |
| 11/2022 | Novadip Biosciences | Series B | 23.4M |
| 10/2021 | Novadip Biosciences | Series B | 0 |
| 3/2011 | Lightwire | Venture Round | 14M |
| 7/2012 | Juventas Therapeutics | Series B | 0 |
| 8/2007 | BioProcessors | Series C | 10M |
| 9/2015 | Novadip Biosciences | Series A | 0 |
| 11/2012 | Resolve Therapeutics | Series B | 5.8M |
| 8/2018 | Paradigm Diagnostics | Series B | 0 |
| 9/2016 | Caringo | Series B | 8.8M |
| 7/2018 | Morrow Optics | Series A | 0 |
| 2/2013 | Dezima Pharma | Venture Round | 18.6M |
| 7/2003 | BioProcessors | Series B | 13M |
| 1/2022 | Paragraf | Series B | 60M |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 11/2021 | Cambridge Epigenetix | Series D | 0 |
| 1/2015 | Vaultive | Series B | 8M |
| 3/2020 | ABL Space Systems | Series A | 0 |
| 4/2015 | Ralexar Therapeutics | Series A | 26.9M |
| 2/2012 | Vaultive | Series A | 10M |
| 2/2016 | Svelte Medical Systems | Private Equity Round | 44.4M |
| 3/2014 | Svelte Medical Systems | Equity | 5M |
| 1/2019 | BrightVolt | Convertible Note | 6M |
| 9/2015 | Vorago Technologies | Series D | 10M |
| 1/2014 | TigerConnect | Series B | 23M |
| 2/2008 | TherOx | Venture Round | 30M |
| 1/2007 | Achronix Semiconductor | Series A | 0 |
| 10/2008 | Achronix Semiconductor | Series B | 0 |
| 7/2019 | DUST Identity | Series A | 10M |
| 11/2018 | DUST Identity | Seed Round | 2.3M |
| 2/2016 | Akarna | Series B | 15M |
| 11/2011 | Oxyrane | Series D | 26.5M |
| 10/2021 | BrightVolt | Series B | 0 |
| 1/2007 | Ception Therapeutics | Series C | 63M |
| 11/2015 | Ovizio | Venture Round | 8.5M |
| 4/2007 | Xoft | Series D | 0 |
| 9/2014 | Kateeva | Series D | 38M |
| 5/2016 | Kateeva | Series E | 0 |
| 10/2014 | Cambridge Epigenetix | Series A | 5.5M |
| 3/2016 | Cambridge Epigenetix | Series B | 21M |
| 9/2018 | Cambridge Epigenetix | Series C | 30M |
| 3/2009 | BioVex | Venture Round | 40M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 7/2005 | TherOx | Venture Round | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 6/2006 | BioProcessors | Series C | 18M |
| 5/2011 | Resolve Therapeutics | Series A | 2M |
| 5/2019 | Paradigm Diagnostics | Series B | 0 |
| 8/2012 | Achronix Semiconductor | Venture Round | 0 |
| 6/2021 | Phase Four | Series B | 0 |
| 9/2016 | BrightVolt | Series B | 12M |
| 8/2016 | Vuv Analytics | Series B | 6.5M |
| 1/2017 | Zeotap | Series B | 13M |
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 7/2022 | Morrow Optics | Angel Round | 0 |
| 7/2019 | PlanetIQ | Series B | 18.7M |
| 3/2009 | Seahorse Bioscience | Series D | 6M |
| 11/2007 | BioVex | Series E | 35M |
| 5/2018 | ChromaCure | Venture Round | 19.6M |
| 3/2018 | Escalier Biosciences | Series B | 19M |
| 8/2007 | FlowCardia | Series C | 0 |
| 2/2012 | TigerConnect | Series A | 11.4M |
| 11/2015 | Fuzzy Logix | Series A | 5.5M |
| 1/2014 | NeXeption | Series A | 21.5M |
| 9/2015 | EXTEN Technologies | Series B | 10.2M |
| 7/2008 | Celleration | Series D | 0 |
| 7/2020 | Zeotap | Series C | 0 |
| 12/2013 | Ario Pharma | Seed Round | 3.1M |
| 1/2022 | Paragraf | Series B | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 11/2021 | Cambridge Epigenetix | Series D | 0 |
| 10/2021 | Novadip Biosciences | Series B | 0 |
| 10/2021 | BrightVolt | Series B | 0 |
| 6/2021 | Phase Four | Series B | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 7/2020 | Zeotap | Series C | 0 |
| 3/2020 | ABL Space Systems | Series A | 0 |
| 1/2020 | NorthSea Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
